Adebrelimab with chemo and radiation for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy and radiation for people with a high-risk type of nasopharyngeal cancer (stage IVA). The goal is to see if this combination helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer confirmed by biopsy.
- Your cancer is stage IVA (specifically T3N2M0).
- You are between 18 and 65 years old.
- You are generally well enough to be up and about (ECOG score 0 or 1).
- You have adequate blood cell counts and kidney/liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding chemotherapy to a combination of immunotherapy and radiation is more effective than immunotherapy and radiation alone for advanced nasopharyngeal cancer. It is for people whose cancer has not spread to distant organs.
This trial tests a new combination of chemotherapy drugs (GP) plus an immunotherapy drug (adebrelimab) before standard treatment for nasopharyngeal cancer. It aims to see if this combination works better than chemotherapy alone for shrinking tumors.
This trial tests whether adding sintilimab (an immune treatment) to standard chemoradiotherapy can improve outcomes for people with high-risk, locally advanced nasopharyngeal (throat) cancer. It may help your immune system work better against the cancer alongside radiation and chemotherapy.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
This trial tests a combination of three treatments—a targeted cancer drug (becotatug vedotin), an immunotherapy drug (PD-1 antibody), and radiation therapy—for nasopharyngeal cancer that has come back after initial treatment. The goal is to see if this combination can shrink the tumor and help you live longer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.